Actively Recruiting
Effectiveness of ECP Therapy in Stable Angina Pectoris Patients
Led by Universitas Padjadjaran · Updated on 2023-09-25
84
Participants Needed
1
Research Sites
178 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
External Counterpulsation (ECP) is a non-invasive therapy using pressured cuff that is performed on patients with refractory stable angina pectoris to relieve symptoms and increase quality of life. In Indonesia, waiting time for getting coronary artery bypass grafting (CABG) procedure for revascularization treatment in stable angina pectoris patients is way longer than international recommendation which correlates with increase morbidity and mortality during the waiting time. Utilization of ECP for such patients who wait for CABG procedure is still unclear. The investigator aim to evaluate efficacy of addition of ECP compared with medical therapy alone for this population. The efficacy is evaluated using measurement from echocardiography result, treadmill test result, and clinical outcome. if applicable, examination of myocardial perfusion using nuclear examination will also be performed.
CONDITIONS
Official Title
Effectiveness of ECP Therapy in Stable Angina Pectoris Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age �3e= 18 years old
- Diagnosed with stable angina pectoris
- Have anatomic vessel disease lesion with 2VD or 3VD
- Indicated for CABG and on the waiting list; or refuse CABG and choose medical therapy only; or decided by doctor for medical therapy alone due to high CABG surgical risk
- Not planned for urgent CABG
- Received minimum optimal medical therapy for at least 2 weeks
- Able and willing to sign informed consent and follow study procedures
- Lives in Bandung City or its neighborhood
- Retired, not actively working during working hours, or willing to take time to participate in research
You will not qualify if you...
- Congestive heart failure
- Chronic heart failure with Functional Class NYHA III - IV
- Left ventricular ejection fraction (LVEF) less than 35%
- Unprotected left main stenosis greater than 50%
- Blood pressure higher than 180/110 mmHg
- Acute coronary syndrome
- Acute heart failure
- Severe aorta regurgitation
- Malignant arrhythmia
- Atrial fibrillation
- Premature ventricular complex
- Peripheral occlusive artery disease
- Phlebitis
- Deep vein thrombosis
- Hemorrhagic diathesis
- Severe chronic kidney disease
- Aortic aneurysm
- Abdominal aneurysm
- Osteoarthritis
- Low back pain
- Pregnancy
- Registered as participant in another clinical study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dr. Hasan Sadikin General Hospital
Bandung, West Java, Indonesia, 40161
Actively Recruiting
Research Team
M
Mohammad R Akbar, MD, FIHA.
CONTACT
B
Badai B Tiksnadi, MD, FIHA.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here